Ophthalmology company Panoptes Pharma successfully closed financing round
Press release 5: 11.02.2015
Download Press Release
Panoptes Pharma Ges.m.b.H, announced today a financing round, led by aws Gründerfonds (aws Founders Fund) with participation from additional and existing investors. The funding will be primarily invested in the further development of Panoptes`lead molecule PP-001 and the exploration of additional clinical indications in ophthalmology such as adenoviral conjunctivitis.
It was agreed not to disclose details about the transaction.
Read more in our Press Release
and note the Cautionary statement regarding forward-looking statements at the end.